🇺🇸 Lignocaine in United States

261 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypotension — 39 reports (14.94%)
  2. Anaphylactic Reaction — 38 reports (14.56%)
  3. Cardiac Arrest — 31 reports (11.88%)
  4. Drug Ineffective — 30 reports (11.49%)
  5. Toxicity To Various Agents — 24 reports (9.2%)
  6. Dyspnoea — 21 reports (8.05%)
  7. Off Label Use — 20 reports (7.66%)
  8. Tachycardia — 20 reports (7.66%)
  9. Drug Interaction — 19 reports (7.28%)
  10. Pyrexia — 19 reports (7.28%)

Source database →

Lignocaine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Cardiovascular approved in United States

Frequently asked questions

Is Lignocaine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Lignocaine in United States?

University of Malaya is the originator. The local marketing authorisation holder may differ — check the official source linked above.